Genistein Implications in Radiotherapy: Kill Two Birds with One Stone

Area of Science:

• Oncology
• Radiotherapy
• Molecular Biology

Background:

• Radiotherapy is a common cancer treatment, but side effects on normal cells limit its efficacy.
• Existing radioprotectors and radiosensitizers often exhibit high toxicity or insufficient tumor radiosensitization.
• Genistein, a soy-derived isoflavone, has emerged as a potential agent to improve radiotherapy outcomes.

Purpose of the Study:

• To evaluate genistein's role in enhancing radiotherapy efficacy.
• To investigate genistein's mechanisms of action in protecting normal cells and sensitizing tumor cells to radiation.

Main Methods:

• Review of preclinical studies on genistein's effects in various cancer models.
• Analysis of genistein's molecular mechanisms, including antioxidant effects, DNA repair inhibition, cell cycle arrest, and apoptosis modulation.

Main Results:

• Genistein protects normal cells via antioxidant effects, reducing oxidative stress, apoptosis, and inflammation.
• Genistein enhances tumor cell radiosensitivity by inhibiting DNA repair, arresting the cell cycle (G2/M phase), generating reactive oxygen species (ROS), and modulating apoptosis.
• Preclinical studies show genistein efficacy in breast, prostate, and lung cancer models.

Conclusions:

• Genistein demonstrates a unique ability to selectively sensitize tumor cells and protect normal cells during radiotherapy.
• Genistein holds promise for improving radiotherapy efficacy and safety, warranting further clinical investigation.
• Future research should focus on optimizing genistein dosage, administration, and combination therapies for clinical application.